Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

January 13, 2015

 Water Treatment and Desalination Innovator Completes First Commercial Year Expanding its International Reach

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

January 13, 2015

 CAMBRIDGE, Mass., January 13, 2015 – Moderna Therapeutics today announced a license and collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna is a pioneer in the development of mRNA Therapeutics™ across a range of therapeutic applications.

Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases

Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases

January 13, 2015

– Study Demonstrated 91.1% Sensitivity and Specificity of 99.4% for Sepsis Pathogen Detection in 3-5 Hours Without the Need for Blood Culture –

– Results From First Large, Multicenter Clinical Trial Demonstrate Breakthrough Potential of T2MR Technology –

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

January 12, 2015

AG-120 would be the second investigational medicine licensed by Celgene and demonstrates strength and progress of cancer metabolism collaboration

Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering

Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering

January 12, 2015

Poster Presented at Keystone Symposium for Precision Genome Engineering and Synthetic Biology

Acceleron Pharma Outlines Corporate Objectives for 2015

Acceleron Pharma Outlines Corporate Objectives for 2015

January 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.

T2 Biosystems to Present at the 33rd Annual J.P. Morgan Healthcare Conference

T2 Biosystems to Present at the 33rd Annual J.P. Morgan Healthcare Conference

January 8, 2015

Company Presentation at 11 a.m. PT January 15, 2015

LEXINGTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the 33rd annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015, at 11 a.m. PT at the Westin St. Francis in San Francisco.

BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview

BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview

January 7, 2015

 - Enrolled first NSCLC patient with KRAS mutation in phase 2 KRAS mutant or squamous histology NSCLC trial based on encouraging clinical activity from ongoing phase 2 trial with goal of rapid advancement to pivotal studies -

Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors

Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors

January 7, 2015

WATERTOWN, MA – January 7, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed Dennis A. Ausiello, MD, to the company’s Board of Directors. With deep experience and a distinguished record of leadership and accomplishment in medicine and scientific research, Dr. Ausiello brings a seasoned and unique perspective to support Blend’s continued growth and advancement as an innovative oncology drug developer.

Moderna Launches New Venture Valera LLC for Infectious Diseases

Moderna Launches New Venture Valera LLC for Infectious Diseases

January 8, 2015

Moderna venture to advance mRNA vaccines and mRNA-based passive immunity therapies

CAMBRIDGE, Mass., Jan. 8, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced the launch of Valera LLC, a new Moderna venture focused exclusively on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases.